Among the most promising emerging therapies, sodium-glucose cotransporter 2 (SGLT2) inhibitors have demonstrated clinical benefits in HFpEF, particularly in patients with comorbid conditions such as type 2 diabetes and obesity. This evidence concerns the gene SLC5A2 and obesity disorder.